Oculis Q3 net loss CHF 16.9 mln, cash boosted to $300 mln

Oculis Holding AG

10/11/2025 21:23

Overview

Oculis Q3 net loss of CHF 16.9 mln, driven by increased R&D expenses

Company's cash position strengthened to nearly $300 mln post-financing

Oculis launches PIONEER program for Privosegtor after FDA meeting

Outlook

Oculis expects DIAMOND Phase 3 trial results for OCS-01 in Q2 2026

Company plans to initiate Licaminlimab trial in Q4 2025

Oculis anticipates PIONEER-1 trial for Privosegtor to start in Q4 2025

Result Drivers

R&D EXPENSES - Increased R&D expenses driven by advancements in clinical development programs, including Phase 3 DIAMOND trials for OCS-01

FINANCING SECURES TRIALS - Recent financing strengthens cash position to support three pivotal trials in optic neuropathies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-CHF 16.86 mln
Q3 Operating Expenses
-CHF 20.54 mln
Q3 Operating Income
CHF 243,000
Q3 Pretax Profit
-CHF 16.84 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Oculis Holding AG is $36.00, about 46.6% above its November 7 closing price of $19.23

Press Release: ID:nGNEccX1V2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)